Technical Analysis for EXAS - Exact Sciences Corporation

Grade Last Price % Change Price Change
grade D 89.78 0.10% 0.09
EXAS closed up 0.1 percent on Thursday, January 16, 2020, on 1.37 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down
Historical EXAS trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Multiple of Ten Bearish Other 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.10%
Stochastic Reached Oversold Weakness 0.10%
Multiple of Ten Bearish Other 0.10%
Outside Day Range Expansion 0.10%
Oversold Stochastic Weakness 0.10%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company's stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for developing tests to detect other gastro-intestinal cancers, primarily esophageal and pancreatic cancer. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Medicine Health Cancer Medical Tests Inflammatory Bowel Disease Pancreatic Cancer Colorectal Cancer Cancer Screening Diagnostic Gastroenterology Mayo Clinic Polyp

Is EXAS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 123.99
52 Week Low 75.35
Average Volume 2,143,286
200-Day Moving Average 100.73
50-Day Moving Average 88.05
20-Day Moving Average 95.72
10-Day Moving Average 96.66
Average True Range 4.03
ADX 27.64
+DI 23.09
-DI 27.11
Chandelier Exit (Long, 3 ATRs ) 93.48
Chandelier Exit (Short, 3 ATRs ) 99.09
Upper Bollinger Band 104.36
Lower Bollinger Band 87.07
Percent B (%b) 0.16
BandWidth 18.07
MACD Line 1.21
MACD Signal Line 2.48
MACD Histogram -1.2636
Fundamentals Value
Market Cap 10.69 Billion
Num Shares 119 Million
EPS -1.29
Price-to-Earnings (P/E) Ratio -69.60
Price-to-Sales 34.69
Price-to-Book 10.86
PEG Ratio -1.87
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 94.61
Resistance 3 (R3) 95.00 93.77 93.81
Resistance 2 (R2) 93.77 92.54 93.58 93.54
Resistance 1 (R1) 91.78 91.78 91.17 91.39 93.27
Pivot Point 90.55 90.55 90.25 90.36 90.55
Support 1 (S1) 88.56 89.32 87.95 88.17 86.29
Support 2 (S2) 87.33 88.56 87.14 86.02
Support 3 (S3) 85.34 87.33 85.76
Support 4 (S4) 84.95